Please type a plus sign (+) inside this box	+
riease type a plus sign (*) inside this box	1

Sheet

of 3

#9.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

SCH 1686 C1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a colection of information unless it contains a va5d OMB control number. Substitute for form 1449A/PTO Complete if Known Application Number 09/619,493 NFORMATION DISCLOSURE July 19, 2000 Filing Date STATEMENT BY APPLICANT First Named Inventor N. Nashed et al. Group Art Unit 1616 (use as many sheets as necessary) **Examiner Name** S. Qazi

Attorney Docket Number

U.S. PATENT DOCUMENTS								
Examiner Initials *	Examiner Initials * Cite No.		Name of I	Patentee or Applicant Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Wher Passages or Releva Figures Appear		
<u> </u>		\	(# Known)			\		0062/nnall
F		 						
\								62
								00
_								
1		<u> </u>	$\overline{}$			\		
-+-	ļ	ļ	$\overline{}$				\ 	
 			$\overline{}$	 				
-+			$\overline{}$				 	
1					-			
		ļ		<u> </u>			 	
	\	<u> </u>					 	
	\	<u> </u>		+			 	
	\vdash			+	 		 	
		 		+				
	\				- ·			
	-t			FORFIG	NPATENT DOC	LUMENTS		
	1	For	eign Patent Do		Name of Patentee		Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ₆
	İ							
							\	
		+			<u> </u>		ļ	A
		+	<u> </u>		\	-		\vdash
			\					 \
		+	 	 		\ ,	 	 \
	l	 	1.1					
			11					\overline{I}
Examiner Signature			11		Date Cons	sidered		}

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

TECH CENTER 1600/2900

ase type a plus sign (+) inside this box

ubstitute for form 1449A/PTO

3

Sheet

PTO/\$B/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a va5d OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 09/619,493 Application Number July 19, 2000 Filing Date First Named Inventor N. Nashed et al **Group Art Unit** 1616 S. Qazi Examiner Name Attorney Docket Number SCH 1686 C1

(use as many sheets as necessary) of | 3

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of T² Cite Examiner the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No. number(s), publisher, city and/or country where published. Initials * Christine P. West, "Inhibition of ovulation with oral progestins-effectiveness in premenstrual syndrome," European BL Journal of Obstetrics & Gynecology and Reproductive Biology, 34 (1990), pp. 119-128 →C. Kirkham, MD., et al., "A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial to Assess the Side Effects of Medroxyprogesterone Acetate in Hormone Replacement Therapy," Obstetrics & Gynecology, Vol. 78, вм No. 1, July 1991, pp. 93-97 L. Dennerstein, et al., "Progesterone and premenstrual syndrome: a double blind crossover trial, "British Medical BN Journal, Vol. 290, June 1, 1985, pp. 1617-1621 Peter J. Schmidt, MD., et al., "Lack of Effect of Induced Menses on Symptoms in Women with Premenstrual во Syndrome," The New England Journal of Medicine, Vol. 324, No. 17, April 25, 1991, pp. 1174-1179 John Bancroft et al., "The Impact of Oral Contraceptives on the Experience of Perimenstrual Mood, Clumsiness, . BP Food Craving and Other Symptoms," Journal of Psychosomatic Research, Vol. 37, No. 2, 1993, pp. 195-202 Cynthia A. Graham, et al., "A Prospective Treatment Study of Premenstrual Symptoms Using a Triphasic Oral BQ Contraceptive," Journal of Psychosomatic Research, Vol. 36, No. 3, 1992, pp. 257-266 Lennart Nilsson et al., "Clinical Studies on Oral Contraceptives-a Randomized, Doubleblind, Crossover Study of 4 Different Preparations (Anovlar® mite, Lyndiol® mite, Ovulen®, and Volidan®)," Acta Obstetrichet Gynecologica _BR Scandinavica," Vol. XLVI, Supplement 8, pp. 2-31 yr. 1967. Johan Cullberg, "Mood Changes and Menstrual Symptoms with Different Gestagen/Estrogen Combinations," Acta Psychiatrica Scandinavica, Supplementum 236, 1972, pp. 9-86 B\$ Sam Silbergeld, Ph.D., MD., et al., "The Menstrual Cycle: A Double-Blind Study of Symptoms, Mood and Behavior, and Biochemical Variables Using Enovid and Placebo," Psychosomatic Medicine, Vol. 33, No. 5 (Septвт Oct 1971), pp. 411-428 Francis J. Kane, "latrogenic Depression in Women," Phenomenology and Treatment of Depression, Copyright BU 1977, pp. 69-81

Examiner Signature	SABIHA QAZI	Date Considered	//	1/15	102	
				_		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

stitute for form 1449A/PTO

ÍNFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known					
Application Number	09/619,493				
Filing Date	July 19, 2000				
First Named Inventor	N. Nashed et al.				
Group Art Unit	1616				
Examiner Name	S. Qazi				
Attorney Docket Number	SCH 1686 C1				

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	BAi	Mabray et al., "Treatment of Common Gynecologic-Endocrinologic Symptoms by Allergy Management Procedures," Obstetrics & Gynecology, Vol. 59, No. 5, May 1982, pp. 560-564	
06)	ВВ	B.P. Appleby, "A Study of Premenstrual Tension in General Practice," British Medical Journal, 2/6/60, pp. 391-393	
	ВС	Stuart L. Smith, "Mood and Menstrual Cycle," pp. 19-59 John fileli	
(3 BD	B. Andersch et al., "Progesterone Treatment of Premenstrual Tension-A Double Blind Study," Journal of Psychosomatic Research, Vol. 29, No. 5, 1985, pp. 489-493	
	BE \	Michael A. Richter, M.D., et al., "Progesterone Treatment of Premenstrual Syndrome," Current Therapeutic Research, Vol. 36, No. 5, Nov. 1984, pp. 840-850	
	8F	Gwyneth A Sampson, "Premenstrual Syndrome: A Double-Blind Controlled Trial of Progesterone and Placebo," Brit. J. Psychiat. (1979), 135, 209-215	
009	BG	Sarah Maddocks, et al., "A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome," Am J Obstet Gynecol, March 1986, pp. 573-581	
3000	ВН	Ellen Freeman, et al., "Ineffectiveness of Progesterone Suppository Treatment for Premenstrual Syndrome," JAMA, Vol. 264, No. 3, July 18, 1990, pp. 349-353	
	Bi√	Lorraine Dennerstein, et al., "Treatment of Premenstrual Syndrome a Double-blind Trial of Dydrogesterone," Journal of Affective Disorders, 11 (1986), pp-199-205	
	вЈ	Gwyneth A. Sampson, et al., "Premenstrual Syndrome A Double-blind Cross-over Study of Treatment with Dydrogesterone and Placebo," British Journal of Psychiatry, 153 (1988), pp. 232-235	
	ВК	Pekka Ylostalo, et al., "Bromocriptine and Norethisterone in the Treatment of Premenstrual Syndrome," Obstetrics & Gynecology, Vol. 58, No. 3, March, 1982, pp. 292-298	

Examiner	SARIHA	OA71	Date	11/1	5/02
Signature	OMBILIA	SHZ1	Considered	1//	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.